Work

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Year: 2020

Type: article

Study design: Clinical Trial

Abstract: Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/wwde-9r73

Authors: Perou, Charles, Collichio, Frances A., Bernard, Philip S., Orlowski, Robert Z., Stijleman, Inge J., Ivanova, Anastasia, Chiu, Wing Keung, Dees, E. Claire, Carey, Lisa A., Irvin Jr., William J.

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, PharmaMar, National Institutes of Health, Takeda Oncology, National Cancer Institute

Awards: G2407663899, G2815350159, G870117454, G9000018574, G9000073604, G9000182874

OpenAlex ID: W4299606548

FWCI:

Cites:

Cited by:

Related to: 10